We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.21B
AUM Growth
-$804M
Cap. Flow
-$184M
Cap. Flow %
-2.96%
Top 10 Hldgs %
40.63%
Holding
166
New
10
Increased
38
Reduced
80
Closed
12

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$32.4M
2
UNH icon
UnitedHealth
UNH
+$23.7M
3
CI icon
Cigna
CI
+$21.4M
4
HUM icon
Humana
HUM
+$20.1M
5
APLS
Apellis Pharmaceuticals
APLS
+$12.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$72.3M
2
MDT icon
Medtronic
MDT
+$64.4M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$33M
4
CRL icon
Charles River Laboratories
CRL
+$17.5M
5
TMO icon
Thermo Fisher Scientific
TMO
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.77%
3 Energy 0.04%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
126
Cytokinetics
CYTK
$11B
$1.09M 0.02%
37,100
– –
MRUS
127
DELISTED
Merus
MRUS
$1.05M 0.02%
44,500
– –
IMCR icon
128
Immunocore
IMCR
$1.78B
$1.03M 0.02%
+19,850
New +$1.17M
VRDN icon
129
Viridian Therapeutics
VRDN
$2.13B
$978K 0.02%
63,770
+19,370
+44% +$370K
INBX
130
DELISTED
Inhibrx, Inc. Common Stock
INBX
$895K 0.01%
48,800
– –
GDX icon
131
VanEck Gold Miners ETF
GDX
$23B
$888K 0.01%
33,000
– –
VTYX
132
DELISTED
Ventyx Biosciences
VTYX
$851K 0.01%
24,500
– –
GEHC icon
133
GE HealthCare
GEHC
$27.6B
$851K 0.01%
+12,500
New +$909K
GPCR icon
134
Structure Therapeutics
GPCR
$3.49B
$847K 0.01%
+16,800
New +$541K
XENE icon
135
Xenon Pharmaceuticals
XENE
$6.32B
$816K 0.01%
23,900
– –
GOOG icon
136
Alphabet (Google) Class C
GOOG
$3.9T
$791K 0.01%
6,000
– –
BCYC
137
Bicycle Therapeutics
BCYC
$270M
$788K 0.01%
39,200
+14,200
+57% +$325K
ABBV icon
138
AbbVie
ABBV
$458B
$710K 0.01%
4,763
-1,411
-23% -$207K
ETNB
139
DELISTED
89bio
ETNB
$605K 0.01%
39,200
-26,000
-40% -$436K
XOP icon
140
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.42B
$577K 0.01%
3,900
– –
PTGX icon
141
Protagonist Therapeutics
PTGX
$8.75B
$500K 0.01%
+30,000
New +$582K
PFE icon
142
Pfizer
PFE
$140B
$317K 0.01%
+9,555
New +$338K
SEER icon
143
Seer Inc
SEER
$108M
$273K ﹤0.01%
123,426
-12,707
-9% -$44K
MCHI icon
144
iShares MSCI China ETF
MCHI
$6.04B
$177K ﹤0.01%
4,100
– –
DGX icon
145
Quest Diagnostics
DGX
$25.1B
$161K ﹤0.01%
1,324
-618
-32% -$82.3K
GDXJ icon
146
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
$161K ﹤0.01%
5,000
– –
GRCL
147
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$109K ﹤0.01%
38,000
-107,646
-74% -$394K
THC icon
148
Tenet Healthcare
THC
$20.1B
$46.1K ﹤0.01%
700
+31
+5% +$2.32K
EQIX icon
149
Equinix
EQIX
$107B
$29.1K ﹤0.01%
40
– –
EVTC icon
150
Evertec
EVTC
$1.83B
$27.5K ﹤0.01%
739
– –
3 4 5
6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2023 Portfolio in Review

As of Q3 2023, Bellevue Group held 166 positions worth $6.21B, down 11% from $7.01B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q3 2023 filing shows 10 new, 38 increased, 80 reduced and 12 closed positions. Its largest new stake was Viatris: 176,848 shares worth $1.74M. The largest sale was Inspire Medical Systems, an estimated $72.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q3 2023 buy was Viatris: 176,848 shares worth $1.74M.
  • Bellevue Group added most to Elevance Health in Q3 2023, an estimated $32.4M increase.
  • Bellevue Group's biggest Q3 2023 reduction was Inspire Medical Systems, cutting an estimated $72.3M.
  • Bellevue Group fully exited Baxter International in Q3 2023, selling an estimated $9.72M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.21B portfolio in Q3 2023.
  • Bellevue Group opened 10 new positions and closed 12 in Q3 2023.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $6.21B.

Based on Bellevue Group's 13F filing for Q3 2023, filed 14 Nov 2023.